We Accelerate Discovery

You are here

Printer

Center for Cell Control

 
On This Page
 

Executive Summary

The goal of NDC is to characterize and quantify nano-molecular components of cells and to precisely control and manipulate these molecules and supramolecular assemblies to improve human health. The Center for Cell Control’s (CCC) strategy to achieve this vision is to precisely control cell function with combinatorial drugs aimed at specific outcomes and measuring signaling complexes by PhosphoFlow or by Tunable Nano Plasmonic Resonators (TNPR) in living cells to ultimately advance therapeutic goals. Our platform integrates real-time molecular detection with cell control. This approach enables response quantification of signaling nanomachineries, such as protein-protein interactions and signal transduction network activity, that guides cell fate under multiple types of stimulation. Using this integrative approach, synergistic or antagonistic interactions between molecular complexes are deciphered by quantifying multiple phosphorylation nodes in the signaling network. This strategy has already been successfully demonstrated and is beginning to link specific signaling nanomachines to translational medicine. Successful examples include in-vitro experiments to inhibit DNA virus infections, to eradicate cancer cells, and to maintain human embryonic stem (hES) cell pluripotency and self-renewal under defined culturing conditions.

 Introduction
Based on our strategy, CCC will realize its vision using the overall plan illustrated here. Combinatorial drug studies have shown potential for a rapid path to translational medicine and also provide a rich information data base for exploring the responses of signaling complexes, or signalosomes, in live cells. Over the past years, CCC has made two milestone advances:
 

  • Identifying relevant signaling complexes in various settings and quantifying their responses, as measured by phosphorylation activity, with single or multiple drug stimulations. Thus, CCC has demonstrated specific coupling between “nano” and medicine.
  • Removing the hurdle of tunable nanoplasmonic resonator (TNPR) mass production. This is an important step toward real-time measurements of signaling complex assembly/disassembly and network activity in live cells.

Figure 1 - Schematic diagram of CCC’s overall vision and goal

NDC Goals

NDC’s overall goal is to:
 

  • Characterize quantitatively molecular scale components or nanomachineries of the cell. This nanomedicine initiative is distinguished from other NDCs by its long-term focus on characterizing cellular processes and their interactions at a level of precision that has not been achieved to date.
  • Precisely control and manipulate these molecules and supramolecular assemblies in living cells.
  • Improve human health.

CCC has developed specific strategy to realize the NDC goal. Our plan is to:

  • Manipulate relevant signal complexes by multiple stimulations for therapeutic purposes.
  • Precisely measure system responses of signaling complexes by first using PhosphoFlow technology and then by tunable plasmonic resonators (TNPR) in living cells.
  • Initiate the process of developing gene profile drug cocktail treatment on non-small cell lung cancer through the clinical collaboration project for improving human health.

NDC accomplishments

I: Manipulating relevant signal complexes by multiple stimulations for therapeutic purposes 

CCC’s first task is to manipulate cell function with combinatorial drugs aimed at specific cellular outcomes or phenotypes, to ultimately advance therapeutic goals. It has been extremely challenging for clinical researchers to determine optimal doses of drugs to use when combined with each other. If a researcher were to test ten different concentrations of six drugs in every possible arrangement, he/she would have one million experimental conditions. We applied feedback system control technique and succeeded in removing this major road block. With only tens of iterative tests, we were able to identify optimized combinatorial drugs. In addition, the dosages of some drugs can be one order of magnitude lower than that of single drug usage. Currently we are working on in-vitro experiments to inhibit virus infections, eradicate cancer cells, and maintain human embryonic stem (hES) cell pluripotency and self-renewal under defined culturing conditions. The inhibition of viral infection VSV and the reactivation of KSHV have been published (ref. 13 and 29).
 

I-1: Optimizing Drug Combination for inhibiting vesicular stomatitis virus (VSV) infection
 

Figure 2 - Example of a rapid convergence to optimal drug cocktailViruses replicate by infecting a host cell and using the host cell’s molecular machinery to create new progeny virions. Consequently, many of the molecular components of the virus and the host cell are similar. Therapeutics that target virus replication thus represent a double edged sword in that though they can efficaciously block viral replication they may also interfere with normal host cellular metabolism. Indeed, many anti-viral therapeutics that work effectively in vitro suffer in the clinical setting by toxic side effects. A central question in the effective clinical management of viral infection thus remains: Is there an optimal method to treat a patient by inhibiting viral replication and still limit or abolish the toxic side effects of the drugs? To limit the side effects of high dose anti-viral therapies, treatments have entailed combinatorial drug use where multiple anti-viral drugs work in concert to limit the replication and spread of virus. We used 5 drugs with 10 concentrations to inhibit SVS infection of NIH 3T3 fibroblast cells. Three of these drugs were interferons (IFN), including IFNa, IFNb, and IFNg. IFNs are naturally produced proteins that are highly effective in organisms to block virus infections by producing an antiviral state. In addition, we used Ribavirin, a broad spectrum anti-viral drugs that is well characterized to stop RNA viruses like VSV. Also, we used puromycin a nonselective terminator of protein synthesis that at low doses can stop the rapid growth of viruses. The property of rapid convergence of the Gur Game is invaluable for regulating complex biological systems. Inhibition of the viral activity, which is defined as the percentage of cells not expressing GFP after incubation with VSV for 13 hours, was considered as the systemic outputs for the optimization of the antiviral activity in the host cells. In the experiment, three sets independent tests were carried out and all rapidly converged to the potent combination again in tens of iterations. Most dramatically, this approach has defined a potent drug combination using a combination of drugs at concentrations ten times less than individual drugs. This will definitely lead to an overall goal of creating a drug combination that is far less toxic while still as effective as high dose combinations.
 
I-2: Optimizing Drug Combination for KSHV Reactivation

Figure 3 - Low GFP output of BC-3 Cells without induction with reactivation drugUnderstanding and controlling the reactivation of viruses are important for developing new viral therapies. In this study, we aimed to maximize the reactivation of Herpesvirus 8 or Kaposi’s Sarcoma-associated Herpesvirus (KSHV) in a GFP transfected body cavity-based lymphoma cell line (BC-3) (Figure). A cocktail with 6 reactivation drugs and 10 concentrations requires 1 million tests which is extremely laborious and time consuming. By using the feedback control scheme, we have demonstrated in several different biological systems that twenty to thirty iterations is sufficient to finding the optimal drug cocktail within millions of possible combinations. At the heart of the closed-loop feedback control scheme is the mathematically well defined stochastic search algorithm that analyzes the system information and establishes the most effective driving inputs, i.e. drug combination.

To implement this KSHV reactivation study, a microfluidic platform was developed that has the capability of live cell imaging and precise cellular environment and stimulation control. Two search algorithms, Gur game and Differential Evolution, were used for the feedback control scheme. In this study, the feedback scheme was able to locate the optimal combination of drugs to reactivate KSHV with less than 30 test iterations for either of the two algorithms. The optimal cocktail was able to perform 49% better than the best performing single drug. Furthermore, the dosage needed in the drug cocktail is much lower that used in single drug cases.

Figure 4 - Fluorescence output of DE cocktail comparison with the outputs from best performing individual drugs concentrations
 II: Precisely measure system responses of signaling complexes

The simultaneous stimulations of relevant signaling nanomachines, such as protein-protein interactions and signal transduction network activities, have been successfully demonstrated to guide cell fate. We are integrating real-time molecular detection, Phosphoflow and TNPR, with cell control. Using this integrative approach, synergistic or antagonistic interactions between molecular complexes are deciphered by quantifying multiple phosphorylation nodes in the signaling network. This strategy has already been successfully demonstrated and is beginning to link specific signaling nanomachines to translational medicine.

II-1: PhosphoFlow Techniques for Quantifying Signaling Nanomachines

Phosphorylation of proteins plays an important role in cellular regulatory mechanisms. We have developed two complementary techniques to quantify the phosphorylation state of signaling protein complexes. In signaling biology, it has become clear that individual signaling molecules are not reflective of the state of a system. Multiple feedback mechanisms, redundancies, and cyclic events make modeling of cell reactivity to environmental influences, such as drugs, particularly daunting. Moreover, the state of the signaling machinery at any given point in time is both a reflection of its history as well as a current position to respond depending upon the environmental stimulus. Systems biologists and network specialists in biomedicine have begun to define signaling complexes, or at least begin identifying the elements of pathways that act as surrogates for the state of a particular pathway. This has led to approaches that both enhance our representations of signaling networks, as well to developing tools that use network states as 'targets' for drug action. Clearly, since viruses and cancer work at the level of modulating the network state, we as biomedical engineers (in the sense that we are attempting to modulate such network states back to health) must understand the means by which networks regulate themselves.

Given the nature of such complex systems, the evolution of eukaryotes in particular has chosen a path of supramolecular complexes with transient interchangeable parts as the basic units of decision-making within cells. Some protein elements of such machine complexes remain as core features of these nanomachines, while others are transiently associated with the nanomachines as they alter the basic function of the nanomachines, or are altered themselves. To faithfully reflect the biology and mechanism of such supramolecular machines and the networks in which they operate, we have chosen to quantify the functional states of many of the sub-elements of these systems via PhosphoFlow techniques.

For instance, NF-kB remains associated with IkB until one of its components (IkB) is phosphorylated. This leads to a dissociation of the NF-kB heterodimer and subsequent phosphorylation of the p65 subunit of that complex. Prior to activation, another supramolecular complex of kinases and inhibitors play a similar and more integrative role by interacting with numerous cellular pathways that impact NF-kB activity. Other examples abound, including the scaffolding proteins of the MAP Kinase pathways (STE5, KSR for MAP-RAS interactions, and MP1) and STAT dimer associations on cytoplasmic tails that lead to their activation and complexes that control the cell cycle. All of these systems must be described not just as the functions of their individual components, but at a level that faithfully reflects the mutable nature of their interactions and the nanomachinery to which they contribute and affect.

We have established approaches and protocols for measuring individual cell phosphorylation and correlations of such events to network states and phenotypic outcomes in response to drug treatments. Coupling of these developed approaches to known 'physical' interaction maps, scaffolds, and other defined nanomachinery within the cells (supramolecular complexes as noted above), will provide a new vision of how to represent the every shifting components of cellular signaling, and will allow us to define the multiple critical inflection points (multi-drug screening against networks as a whole) where modulation of activity of the network as a whole can proceed successfully.

Figure 5 - An example of using the Phospho-Flow technology to look at various phosphorylation sites in the 3T3 mouse fibroblast model
Stimulations.: Mouse IFNa, IFNb, IFNg (100ng/ml), TNFa (1ng/ml). Stains: pStat 1, pStat 3, pStat 5, Total IkBa, pNFkB, pERK, pJNK, pp38

METHODS SYNOPSIS: Cells: 80% confluent (log phase growth) on 12-well plates, culture media volume: 0.5ml (37C), unchanged for at least 24 hrs. Stimulants added directly to wells, mix with gentle swirling motion. After stim. step, add 0.5ml 0.25% Trypsin (4C) and incubate 5' (R.T.) while dislodging cells by drawing up and down with a P1000 pipetteman. Fix by adding 1ml 20% PFA (PBS) (R.T.) to wells, treat for 10' (transfer to FACS tube). Wash 2X PBS (R.T.). Permeabilize w/ cold MeOH (overnight, -80C or 10', 4C), centrifuge (100% MeOH). Barcode: (Pac Blue (PB) X Pac Orange (PO) succinimidyl esters, use 6 points derived from a 3 X 3 labeling matrix), 30' (R.T.). Wash 2X with Staining Medium, pool, stain with primary Abs., 30' (R.T.), wash, stain with second. Abs. 30' (R.T.), wash, evaluate.

II-2: Mass Production of TNPRs
Figure 6 - TNPR release from nanoimprinted substrates 
We have successfully adapted nanoimprint lithography (NIL) for the mass fabrication of TNPRs. Using a NIL process that is designed for metal nanostructures, we have achieved reliable high-yield TNPR arrays over large areas the size of standard microscope slides, or equivalent to 2-3x109 TNPRs at a time. This capability presents two distinct opportunities. First, large-area substrates will enable massive improvement of the throughput of TNPR enhanced extracellular sensing of signaling molecule secretion. This will be achieved by covering the TNPR substrates with arrays of microfluidic channels and studying numerous specimens on the same chip. Second, we can now produce TNPRs in quantities appropriate for ballistic injection (achieved with high viability in pilot studies) and intracellular investigations of signalosome activity. Our current fabrication focus is to continue improving the yield and quality of TNPR solubilization. And also we are continuing efforts in developing a biocompatible sacrificial film to release TNPRs from the substrate into an aqueous medium and the protocols of peptide functionalization for eventual intracellular delivery and signaling pathway sensing.

II-3: OET techniques for Membrane Perforation

The aim of this project is to develop an alternative technique for delivering TNPRs into the intracellular space to monitor phosphorylation events. We are pursuing two methods simultaneously that combine optoelectronic tweezers (OET) with poration capability.

Figure 7 - Cell subjected to 3 laser doses (white x) and corresponding fluorescent image showing highly localized molecular delivery.The first technique involves electroporation. Electroporation is a common technique for the introduction of exogenous molecules across the, otherwise, impermeant cell membrane. Conventional techniques are limited by either low throughput or limited selectivity. We present a novel technique whereby we use patterned light to create virtual electrodes which can induce the parallel electroporation of single cells. This technique seamlessly integrates with OET to provide a single cell manipulation platform as well. Cells are placed in the OET device and are manipulated using patterned light. Then, through a change in device bias, only cells that are illuminated in the device are electroporated. We have successfully demonstrated the delivery of fluorescent molecules into the cell. Additionally, we have completed a study proving that cells remain viable following electroporation. Since we are able to perform this technique in parallel, with single cell resolution, we are able to extract out the optimal field dosage to deliver a molecule to a cell without harming it. These results have recently been published in the Royal Society of Chemistry’s Lab on a Chip journal.
 
The second technique uses a femtosecond laser to create highly localized holes in the cell membrane. Due to short pulse widths, damage to the cell outside of the focal point of the laser beam is minimized. This allows us to selectively deliver molecules and particles to specific regions of the cell. We have successfully created pores ranging up to 500 nm in diameter in the cell membrane. We have used this technique to selectively deliver a fluorescent dye to only a small area of the cell. By combining this technique with the ability of OET to concentrate nanoparticles near a cell, we can create large concentrations of probes near the laser-induced membrane pore allowing for highly efficient and localized delivery. By combining OET with membrane poration capability, OET provides a means to efficiently deliver plasmonic probes (TNPRs) into the cell to monitor phosphorylation and other cellular kinetic events.

III: Drug cocktail treatment on non-small cell lung cancer through clinical collaboration

We are currently using techniques such as combinatorial drug cocktail technology and phosphor-flow technology to provide a pathway towards translational medicine. For lung cancer, we focus on assessing combination drug cocktail therapies tailored to gene array profiles, sensitivities of individual tumors, and lower toxicity to non-cancer lung cells. By using the data obtained from the Herpesvirus reactivation model we are also investigating the kinetics of cellular machines under combinational drug therapies. The integration of mathematic approaches for tailoring drug combinations, kinetic behavior of cellular response, and PhosphoFlow analysis techniques will allow a personalized medicine approach that targets susceptible pathways in individual patients and enable clinical translations of these investigations for patients with lung cancer.

III-1: Effect of five drug combinations on lung cancer cells and normal cells

We have determined the single drug dose response curve for (SAHA, Pioglitazone, Celecoxib, Cisplatinum and Erlotinib) selected out of the screened drugs (SAHA, Pioglitazone, Celecoxib, Cisplatinum, Erlotinib, Rapamycin, Paclitaxel, Lapatinib, Alimta, Erbitux and Velcade) on the lung cancer cell line A549 and the normal lung fibroblast cell AG02603. From the single drug dose response curves, we have selected five drugs (SAHA, Pioglitazone, Celecoxib, Cisplatinum and Erlotinib) and their concentration ranges to test their combinatory impact. SAHA is inhibitor of histone deacetylase (HDAC) 1 and 3; Pioglitazone selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPARγ); Celecoxib is a highly selective COX-2 inhibitor and primarily inhibits this isoform of cyclooxygenase (inhibition of prostaglandin production); Cisplatinum complexes are formed in cells, which bind and cause cross-linking of DNA that interferes with cell division -- ultimately triggering apoptosis, or programmed cell death; Erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the ATP binding site of the receptor. These drugs have multiple cellular targets and their interactions are difficult to predict.

We have measured the cellular ATP levels in response to combinations of five drugs on A549 cells and the corresponding erlotinib-resistant A549T cells. To compare the drug effort on different kinds of cells, we also measured the cellular responses of a different lung cancer cell H358 cells and the normal lung fibroblast cell AG02603 (non-cancer cell as control). Mathematical models of the relationships between input drug combinations and output cellular responses were generated. Based on initial analysis we can see that there is a significant difference between the responses of normal and cancer cells to the same set of drugs combinations. Additionally, the drug-resistant cell line exhibited a response profile similar to the non-resistant cell line in response to treatment by combinations of drugs, which suggests that drug combinations can be effective in treating patients who have developed drug-resistance or to prevent the emergence of drug-resistance at the initiation of therapy. Once the results from the in vitro studies have been established we will move towards animal testing of the drug combination therapy.
 

Figure 8 - Schematic diagram showing the clinical collaboration work

Pathway to Medicine

Combinatorial drug technology places the CCC at a strategic position for examining nanoscale activities, such as signaling complex phosphorylation, to rapidly move toward translational medicine. CCC received a clinical collaboration award headed by Dr. Steve Dubinett. This project is applying a rapid search scheme for lung cancer drug discovery that will move to small animal testing in the second year of effort.

Lung cancer is the leading cause of death in the United States and worldwide. It is estimated that lung cancer results in more than 1 million deaths per year worldwide and in the United States, causes approximately one death every 4 minutes. These devastating statistics suggest that an entirely new approach is necessary for the treatment and prevention of lung cancer. Although smoking cessation has made an impact in lung cancer incidence, former smokers remain at an elevated risk of lung cancer for many years. Our current research is to develop a novel system for the optimization of drug combinations for lung cancer therapy by utilizing an artificial neural network modeling algorithm. Our approach will determine optimal combinations of multiple drugs against panels of well characterized drug resistant lung cancer cell lines. These cell lines are being characterized both in terms of their gene array expression profiles and their responses to drugs so that we can ultimately define novel combination therapies targeted to specific genetic abnormalities, working through identified signalosomes.

 References

Kuraishy, A.I., French, S.W., Sherman, M., Herling, M., Jones, D., Wall, R., and Teitell, M.A. TORC2 Regulates Germinal Center Repression of the TCL1 Oncoprotein to Promote B Cell Development and Inhibit Transformation. Proc. Natl. Acad. Sci. USA 104:10175-10180, 2007 PMCID: PMC1891214

  1. Dawson, D.W., Hong, J.S., Shen, R., French, S.W., Troke, J.T., Wu, Y.-Z., Chen, S.-S., Gui, D., Regelson, M., Marahrens, Y., Morse III, H.C., Said, J.W., Plass, C., and Teitell, M.A. Global Assessment of DNA Methylation in a Mouse Model of B Cell Lymphoma Identifies Epigenetic Silencing of a Variant Transcript of EphA7 in Lymphocytes. Oncogene 26:4243-4252, 2007 (PMID 17230020) NIHMSID: NIHMS131749
  2. Reed, J., Mishra, B., Pittenger, B., Magonov, S., Troke, J.J., Teitell, M.A. and Gimzewski, J.K. Single Molecule Transcription Profiling with AFM. Nanotechnology, 18: 044032, 2007 NIHMSID: NIHMS131750
  3. Weihs, D., Mason, T.G., and Teitell, M.A. Effects of Cytoskeletal Disruption on Transport, Structure, and Rheology within Mammalian Cells. Physics of Fluids, 19:103102-1, 2007 NIHMSID: NIHMS131751
  4. Ho, C.M. and Chen J.M., “The Convergence of bio, nano, and information technology”, IEEE Nanotechnology Magazine (cover article), v.1. p. 18-21. 2008
  5. Weihs, D., Teitell, M.A., and Mason, T.G. Simulations of complex particle transport in heterogeneous active liquids. Microfluid Nanofluid 3:227-237. 2007
  6. Wong, P.K., Yu, F., Sun R., and Ho, C.M., “Unraveling Gene Regulatory Networks Using an Integrated Microfluidic Platform”, IEEE Transactions of Nanotechnology, accepted, 2007
  7. Chow, EKH., Chu, B., Cheng G., Tai, YC., Pierstorff, P., and Ho., D. Copolymer-mediated Fabrication of Versatile Electro-Active and Inflammation Attenuating Substrates for Biological Interrogation. NANO: Brief Reports and Reviews 2 (6): 351-359, 2007
  8. Ohta, A. T., Jamshidi, A., Valley, J. K., Hsu, H. Y., and Wu, M. C, "Optically actuated thermocapillary movement of gas bubbles on an absorbing substrate," Applied Physics Letters, vol. 91, p. 074103, 2007 NIHMSID: NIHMS130823
  9. Valley, J.K., Jamshidi, A., Ohta, A.T., Hsu, H.Y., Wu, M.C. Operational Regimes and Physics Present in Optoelectronic Tweezers. J. Microelectromechanical Systems, 17, 342-350, 2008 PMCID: PMC2600567
  10. Jamshidi, A., Pauzauskie, P. J., Schuck, P. J., Ohta, A. T., Chiou, P.-Y., Chou, J., Yang,P., and Wu, M. C., "Dynamic manipulation and separation of individual semiconducting and metallic nanowires," Nature Photonics, vol. 2, pp. 86-89, 2008 (Feature on Cover) NIHMSID: NIHMS130772
  11. Chow, EKH., Pierstorff, E., Cheng, G., and Ho, D. Copolymeric Nanofilm Platform for Controlled and Localized Therapeutic Delivery ACS Nano, 2(1), 33–40, 2008 (New collaboration with Professor Dean Ho at Northwestern University, in the development of a drug delivery platform for multiple types of drugs using copolymeric nanofilms.)
  12. Wong, P.K., Yu, F., Shahangian, A., Cheng, G., Sun, R., and Ho, C.M., “Closed-loop Control of Cellular Functions Using Combinatory Drugs Guided by a Stochastic Search Algorithm" PNAS, (to appear), 2008
  13. Lillehoj, P., Li, N, Tsutsui, H., and Ho, C.M. “A Compact Microfluidic Continuous Flow Separator For Particle And Cell Sorting”, IEEE MEMS Tech Digest, 292-295, 2008
  14. Li, N., Wong, P.K., Lin, J. And C.M. Ho, C.M., “ Transfection of Molecular Beacons in Microchannels under Flow and No-Flow Conditions” IEEE MEMS Tech Digest, 260-263, 2008
  15. Li N. and Ho, C.M., Aptamer-Based Optical Probes with Separated Molecular Recognition and Signal Transduction Modules” J. Am. Chem. Soc. V.130, 2380-2381, 2008
  16. Ho, C.M., Ho, S., Wong, P.K., and Nassef, H., “Control Systems with Large Parameter Spaces”, Proceedings of IUTAM, accepted, 2008
  17. Park, S., Pan, C., Wu, T.-H., Klos, C., Kalim, S., Callahan, C.E., Teitell, M.A., and Chiou, E.P.Y. Floating Electrode Optoelectronic Tweezers (FEOET): Light-Driven Dielectrophoretic Droplet Manipulation in Electrically Insulating Oil. Applied Physics Letters, 151101, 2008 PMCID: PMC2682741
  18. Reed, J., Frank, M., Troke, J.J., Schmit, J., Han, S., Teitell, M.A., and Gimzewski, J.K. High-Throughput Cell Nano-Mechanics with Mechanical Imaging Interferometry. Nanotechnology, 19, 235101, 2008 NIHMSID: NIHMS131720
  19. Reed, J., Troke, J.J., Schmit, J., Han, S., Teitell, M.A., and Gimzewski, J.K. Cellular Dynamism During Force Propagation Revealed by Live Cell Interferometry. ACS Nano, 2:841-846, 2008 PMID 19206480. NIHMSID: NIHMS131722
  20. Valamehr, B., Jonas, S.J., Polleux, J., Qiao, R., Guo, S., Gschweng, E.H., Stiles, B., Kam, K., Luo, T.J., Witte, O.N., Liu, X., Dunn, B., Wu, H. Hydrophobic Surfaces for Enhanced Differentiation of Embryonic Stem Cell-Derived Embryoid Bodies. Proc Natl Acad Sci U S A. Sep 23;105(38):14459-64, 2008. (Spotlight in ACS CHEMICAL BIOLOGY VOL.3 NO.10)2008 PMCID: PMC2567159
  21. Yim T.J., Wang Y. and Zhang X., "Synthesis of a gold nanoparticle dimer plasmonic resonator through two-phase-mediated functionalization", Nanotechnology, Vol.19, 435605, 2008 NIHMSID: NIHMS131715
  22. Wu D.M., Liu Z.W., Sun C., and Zhang X., "Super-Resolution Imaging by Random Adsorbed Molecule Probes", Nano Letters , 8, 1159, 2008 PMID: 18321073 [PubMed – indexed for MEDLINE] NIHMSID: NIHMS131716
  23. Wang S., Szobota S., Wang Y., Volgraf M., Liu Z.W., Sun C., Trauner D., Isacoff E.Y., and Zhang X., "All Optical Interface for Parallel, Remote, and Spatiotemporal Control of Neuronal Activity",Nano Letters , 7, 3859, 2007 (PMID: 18034506)
  24. Mai J.Y., Fok L., Gao H.F., Zhang X., Poo M.M., "Axon Initiation and Growth Cone Turning on Bound Protein Gradients", Journal of Neuroscience, 29, 7450, 2009 (PMID:19515913)
  25. Wang S., Foo W.P., Warrier A., Poo M.M., Heilshorn S.C., and Zhang X., "Gradient Lithography of Engineered Proteins to Fabricate 2D and 3D Cell Culture Microenvironments" Biomedical Microdevices, published on line, 2009 DOI: 10.1007/s10544-009-9329-1 (PMID: 19495986)
  26. Ulmanella, U. and Ho, C.M., “Molecular Effects on Boundary Condition in Micro/Nanoliquid Flows”, Phys. Fluids 20, 101512, 2008 PMID: 19857719 [PubMed]. NIHMSID: NIHMS131388
  27. Li, N. and Ho, C.M., “Photolithographic Patterning of Organosilane monolayer for generating large area two-dimensional B lymphocyte arrays”, The Royal Society of Chemistry, Lab on a Chip, 8, 2105-2112, 2008 PMID: 19023473. NIHMSID: NIHMS131497
  28. Sun, C.P., Usui, T., Yu, F., Al-Shyoukh, I., Shamma, J., Sun, R., and Ho, C.M., “Integrative Systems Control Approach for Reactivating Kaposi’s Sarcoma-associated herpesvirus (KSHV) with Combinatory Drugs”, Integr. Biol., 1, 123-130, 2009 NIHMSID: NIHMS130721
  29. Wong, T.S., Brough, B. and Ho, C.M., “Creation of Functional Micro and Nanodevices through Top-down and Bottom-up Approaches”, Molecular and Cellular Biomechanics, Vol. 6, No. 1, pp. 1-55, 2009 NIHMSID: NIHMS130764
  30. Tsutsui, H. and Ho, C. M., “Cell separation by non-inertial force fields in microfluidic systems” Mechanics Research Communications, vol, 36, pp. 92–103, 2009 NIHMSID: NIHMS130766
  31. Teitell, M.A., Kalim, S., Schmitt, J., and Reed, J. Biomechanics of Single Cells and Cell Populations. In Ho, D: Nanodiamonds for Biology and Medicine, Springer Press, Inc., Norwell, MA, USA. In press, 2009
  32. Valley, J.K., Neale, S.L., Hsu, H.Y., Ohta, A.T., Jamshidi, A., Wu, M.C. Parallel single-cell light-induced electroporation and dielectrophoretic manipulation. Lab Chip, 2009 DOI:10.1039/B821678A. PMID: 19495455 [PubMed - in process] NIHMSID: NIHMS131945
  33. Pauzauskie, P.J., Jamshidi, A., Valley, J.K., Satcher, J.H., Wu, M.C. Parallel Trapping of Multiwalled Carbon Nanotubes with Optoelectronic Tweezers. (Submitted).
  34. Neale, S.L., Ohta, A.T., Hsu, H.Y., Valley, J.K., Jamshidi, A., Wu, M.C. Trap Profiles of Projector Based Optoelectronic Tweezers (OET) with HeLa Cells. (Submitted). 2009 PMID: 19333286 [PubMed – indexed for MEDLINE] NIHMSID: NIHMS131506
  35. Jamshidi, A., Neale, S. L., Yu, K., Pauzauskie, P. J., Schuck, P. J., Valley, J. K., Hsu, H.Y., Ohta, A. T., Wu, M. C. NanoPen: Dynamic, Low-Power, and Light-Actuated Patterning of Nanoparticles. Nano Letters. 2009 DOI 10.1021/nl901239a. PMID: 19588985 [PubMed – as supplied by publisher]. NIHMSID: 136585.
  36. Cubukcu E, Zhang S, Park YS, Bartal G, Zhang X. Split ring resonator sensors for infrared detection of single molecular monolayers. Applied Physics Letters 95, 043113. July 2009 DOI 10.1063/1.3194154

Contact Information

Principle Investigator

Chih-Ming Ho, Ph.D.
Ben Rich-Lockheed Martin Professor
UCLA Distinguished Professor
Director of the Center for Cell Control (CCC)
Mechanical and Aerospace Engineering Department
School of Engineering and Applied Science
Engineering IV, Room 38-137J
420 Westwood Plaza
Los Angeles, CA 90095-1597
Phone: 310-825-9993
Fax: 310-206-2302
Email: chihming@ucla.edu
Website: http://ho.seas.ucla.edu Exit Disclaimer
 Co-Investigators

Garry Nolan, Ph.D.
Professor, Dept. of Molecular Pharmacology, Microbiology and Immunology
Stanford University
Fairchild Building, D300
300 Pasteur Drive
Stanford, CA 94305-5124
Email: gnolan@stanford.edu
Website: http://www.stanford.edu/group/nolan/ Exit Disclaimer
 
Genghong Cheng, Ph.D.
Professor, Dept. of Microbiology, Immunology and Molecular Genetics
University of California Los Angeles
8-240 Factor Building
10833 Le Conte Avenue
Los Angeles, CA 90095-1781
Tel: 310-825-8896
Fax: 310-206-5553
Email: genhongc@microbio.ucla.edu
Website: http://www.mimg.ucla.edu/faculty/cheng/genhong.html Exit Disclaimer
 
Hong Wu, M.D., Ph.D.
Professor, Molecular & Medical Pharmacology
University of California Los Angeles
CHS 23-214
Tel: 310-825-5160
Fax:310 267 0242
Email: HWu@mednet.ucla.edu
Website: http://labs.pharmacology.ucla.edu/hwulab/ Exit Disclaimer
 
Michael Teitell, M.D., Ph.D.
Chief, Pediatric and Developmental Pathology
David Geffen School of Medicine at UCLA
675 Charles Young Dr. South
MRL 4-762
Los Angeles, CA 90095-1932
Tel: (310) 206-6754
Fax: (310) 267-0382
Email: mteitell@mednet.ucla.edu

 
Ming Wu, Ph.D.
Professor, Department of Electrical Engineering and Computer Sciences
University of California, Berkeley
261M Cory Hall
#1770 Berkeley, CA 94720-1770
Tel: 510-643-0808
Fax: 510-666-2502
Email: wu@eecs.berkeley.edu
Website: http://www.eecs.berkeley.edu/Faculty/Homepages/wu.html Exit Disclaimer
 
Ren Sun, Ph.D.
Professor, Molecular & Medical Pharmacology
University of California Los Angeles
10-155 Factor
CAMPUS - 173517
Los Angeles, CA 90095
Tel: 310-794-5557
Email: rsun@mednet.ucla.edu
Website: http://faculty.pharmacology.ucla.edu/institution/personnel?personnel_id=45881 Exit Disclaimer
 
Steven Dubinett, M.D.
Chief, Pulmonary and Critical Care Medicine
David Geffen School of Medicine at UCLA
37-131 Center for Health Sciences
10833 Le Conte Avenue
Los Angeles, CA 90095-1690
Tel: 310-267-2725
Fax: 310-267-2829
Email: sdubinett@mednet.ucla.edu
Website: http://www.uclahealth.org/body.cfm?id=479&action=detail&ref=11751 Exit Disclaimer
 
Xiang Zhang, Ph.D.
Chancellor's Professor
5130 Etcheverry Hall, Mailstop 1740
University of California at Berkeley
Berkeley, CA 94720-1740
Tel: 510-643-4978
Email: xzhang@me.berkeley.edu
Website: http://www.me.berkeley.edu/faculty/zhang/ Exit Disclaimer
 
Yong Chen, Ph.D.
Professor, Dept. of Mechanical and Aerospace Engineering
University of California Los Angeles
Room 38-137G, Engineering IV
University of California,
Los Angeles, CA 90095-1597
Tel: 310-206-2453
Fax: 310-206-2302
E-mail: yongchen@seas.ucla.edu
Website: http://chen.seas.ucla.edu Exit Disclaimer

Up to Top